CN111247153B - 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1，3]间二氧杂环戊烯并[4，5-f]吲哚-7-基)吡咯-2，5-二酮的固体形式 - Google Patents

3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1，3]间二氧杂环戊烯并[4，5-f]吲哚-7-基)吡咯-2，5-二酮的固体形式 Download PDF

Info

Publication number
CN111247153B
CN111247153B CN201880059690.4A CN201880059690A CN111247153B CN 111247153 B CN111247153 B CN 111247153B CN 201880059690 A CN201880059690 A CN 201880059690A CN 111247153 B CN111247153 B CN 111247153B
Authority
CN
China
Prior art keywords
ing
solvate
solid form
volume ratio
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880059690.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111247153A (zh
Inventor
张亚民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinesitherapy Co
Original Assignee
Kinesitherapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63405430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111247153(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kinesitherapy Co filed Critical Kinesitherapy Co
Priority to CN202311213594.XA priority Critical patent/CN117362305A/zh
Publication of CN111247153A publication Critical patent/CN111247153A/zh
Application granted granted Critical
Publication of CN111247153B publication Critical patent/CN111247153B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
CN201880059690.4A 2017-08-11 2018-08-10 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1，3]间二氧杂环戊烯并[4，5-f]吲哚-7-基)吡咯-2，5-二酮的固体形式 Active CN111247153B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311213594.XA CN117362305A (zh) 2017-08-11 2018-08-10 9-ing-41的固体形式

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762544277P 2017-08-11 2017-08-11
US62/544,277 2017-08-11
PCT/US2018/046203 WO2019032958A1 (en) 2017-08-11 2018-08-10 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311213594.XA Division CN117362305A (zh) 2017-08-11 2018-08-10 9-ing-41的固体形式

Publications (2)

Publication Number Publication Date
CN111247153A CN111247153A (zh) 2020-06-05
CN111247153B true CN111247153B (zh) 2024-04-02

Family

ID=63405430

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880059690.4A Active CN111247153B (zh) 2017-08-11 2018-08-10 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1，3]间二氧杂环戊烯并[4，5-f]吲哚-7-基)吡咯-2，5-二酮的固体形式
CN202311213594.XA Pending CN117362305A (zh) 2017-08-11 2018-08-10 9-ing-41的固体形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311213594.XA Pending CN117362305A (zh) 2017-08-11 2018-08-10 9-ing-41的固体形式

Country Status (16)

Country Link
US (3) US11136334B2 (https=)
EP (1) EP3665176B1 (https=)
JP (3) JP7424639B2 (https=)
KR (3) KR20250070131A (https=)
CN (2) CN111247153B (https=)
AU (3) AU2018313259B2 (https=)
BR (1) BR112020002892A2 (https=)
CA (1) CA3072240A1 (https=)
DK (1) DK3665176T3 (https=)
ES (1) ES2974328T3 (https=)
FI (1) FI3665176T3 (https=)
IL (2) IL313800A (https=)
MX (3) MX2020001547A (https=)
PL (1) PL3665176T3 (https=)
PT (1) PT3665176T (https=)
WO (1) WO2019032958A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3697794T (pt) * 2017-10-16 2026-03-04 Actuate Therapeutics Inc Formas sólidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona
EP3793545A4 (en) * 2018-05-17 2022-04-06 Actuate Therapeutics Inc. TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS WITH BETA INHIBITORS IN THE FORM OF GLYCOGEN SYNTHASE KINASE 3
JP2025525407A (ja) 2022-06-27 2025-08-05 アクチュエイト セラピューティクス インク． エルラグルシブの経口剤形

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY156701A (en) 2009-12-23 2016-03-15 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
From a Natural Product Lead to the Identification of Potent and Selective Benzofuran-3-yl-(indol-3-yl)maleimides as Glycogen Synthase Kinase 3 Inhibitors That Suppress Proliferation and Survival of Pancreatic Cancer Cells;Irina N. Gaisina等;《J. Med. Chem.》;20090316;第1853-1863页，表1化合物26，Scheme 1，第1854页左栏第2段-1855页，第1860页左栏第4段 *
Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer;Krishnendu Pal等，;《Mol Cancer Ther.》;20131210;第285-296页，图1 *

Also Published As

Publication number Publication date
CN117362305A (zh) 2024-01-09
US20220009939A1 (en) 2022-01-13
JP7424639B2 (ja) 2024-01-30
FI3665176T3 (fi) 2024-03-20
US20250115616A1 (en) 2025-04-10
IL272556B1 (en) 2024-09-01
EP3665176B1 (en) 2024-01-24
AU2023201059B2 (en) 2025-04-03
DK3665176T3 (da) 2024-03-25
US11136334B2 (en) 2021-10-05
BR112020002892A2 (pt) 2020-08-04
ES2974328T3 (es) 2024-06-26
PL3665176T3 (pl) 2024-06-17
MX2020001547A (es) 2020-08-03
US20200223861A1 (en) 2020-07-16
KR20240063198A (ko) 2024-05-09
AU2025202936A1 (en) 2025-05-15
JP2026012715A (ja) 2026-01-27
JP2020530497A (ja) 2020-10-22
AU2023201059A1 (en) 2023-03-23
AU2018313259B2 (en) 2022-11-24
CA3072240A1 (en) 2019-02-14
KR20200040799A (ko) 2020-04-20
IL313800A (en) 2024-08-01
WO2019032958A1 (en) 2019-02-14
JP2023156372A (ja) 2023-10-24
KR102700883B1 (ko) 2024-09-02
MX2024003249A (es) 2024-04-04
EP3665176A1 (en) 2020-06-17
IL272556A (en) 2020-03-31
CN111247153A (zh) 2020-06-05
AU2018313259A1 (en) 2020-02-27
IL272556B2 (en) 2025-01-01
JP7778750B2 (ja) 2025-12-02
US12145943B2 (en) 2024-11-19
KR20250070131A (ko) 2025-05-20
PT3665176T (pt) 2024-03-13
MX2023005875A (es) 2023-06-05

Similar Documents

Publication Publication Date Title
JP7778750B2 (ja) ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
KR102576964B1 (ko) 헤테로시클리덴 아세트아미드 유도체의 결정
US20250115615A1 (en) Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
CN105294717B (zh) 一种egfr抑制剂的盐、晶型及其用途
HK40106022A (zh) 9-ing-41的固体形式
JPWO2004020433A1 (ja) 新規結晶
WO2019001551A1 (zh) 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
BR122025019554A2 (pt) Forma sólida de 3-(5-flúor-benzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5- f]indol-7-il)pirrol-2,5-diona, seus usos, composição farmacêutica e processo para preparar a mesma
BR112020007538B1 (pt) Forma sólida, processo para preparar a forma sólida, composição farmacêutica, processo para preparar a composição farmacêutica e uso da forma sólida
CN105461698A (zh) 西地尼布盐及其晶型、以及其制备方法和药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant